Proteon logo     Print Page | Close Window

SEC Filings

S-1
PROTEON THERAPEUTICS INC filed this Form S-1 on 09/16/2014
Entire Document
 


Proteon Therapeutics, Inc.

Statements of Operations and Comprehensive Loss

(in thousands, except share and per share data)

 
  Year Ended
December 31,
  Six Months Ended
June 30,
 
 
  2012   2013   2013   2014  
 
   
   
  (unaudited)
 

Operating expenses:

                         

Research and development

  $ 5,907   $ 3,994   $ 2,003   $ 2,785  

General and administrative

    2,089     3,128     1,417     1,656  
                   

Total operating expenses

    7,996     7,122     3,420     4,441  
                   

Loss from operations

    (7,996 )   (7,122 )   (3,420 )   (4,441 )

Other income (expense):

                         

Investment income

    20     4     3     3  

Interest expense

        (861 )       (857 )

Other income (expense)

    6     67     5     (99 )
                   

Total other income (expense)

    26     (790 )   8     (953 )
                   

Net loss

  $ (7,970 ) $ (7,912 ) $ (3,412 ) $ (5,394 )
                   

Unrealized gain (loss) on available-for-sale investments

    (5 )   (1 )       23  
                   

Comprehensive loss

  $ (7,975 ) $ (7,913 ) $ (3,412 ) $ (5,417 )
                   
                   

Reconciliation of net loss to net loss attributable to common stockholders:

   
 
   
 
   
 
   
 
 

Net loss

  $ (7,970 ) $ (7,912 ) $ (3,412 ) $ (5,394 )

Accretion of redeemable convertible preferred stock to redemption value

    (6,133 )   (6,119 )   (3,039 )   (3,409 )
                   

Net loss attributable to common stockholders

  $ (14,103 ) $ (14,031 ) $ (6,451 ) $ (8,803 )
                   
                   

Net loss per share attributable to common stockholders—basic and diluted

  $ (3.85 ) $ (3.76 ) $ (1.76 ) $ (2.31 )
                   
                   

Weighted-average number of common shares used in net loss per share attributable to common stockholders—basic and diluted

    3,659,790     3,732,436     3,659,790     3,812,904  
                   
                   

Pro forma net loss per share attributable to common stockholders—basic and diluted (unaudited)

        $ (0.10 )       $ (0.04 )
                       
                       

Pro forma weighted-average number of common shares used in net loss per share attributable to common stockholders—basic and diluted (unaudited)

          72,457,068           107,333,127  
                       
                       

   

See accompanying notes to financial statements

F-4